-->
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Type Segment
1.2.2. Molecule Type Segment
1.2.3. Service Segment
1.2.4. Therapeutic Areas Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Pharmaceutical CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Rate of Clinical Research to Boost Demand For Outsourcing Services
3.2.1.2. Surge in the Demand for Personalized Medicine and Advanced Therapeutics
3.2.1.3. Rising Mergers and Collaboration Activities in the CRO Market
3.2.1.4. Growing Demand for Outsourcing Services Across Developing Economies
3.2.1.5. Rising Focus of Life Sciences Companies on Their Core Competencies
3.2.2. Market restraint analysis
3.2.2.1. Compliance Issues While Outsourcing
3.2.2.2. Quality Issues of CRO Services
3.2.2.3. Intellectual Property Right Issues
3.3. Technology Advancements in Pharmaceutical CRO Industry
3.4. R&D Investment Perspective, by Key Sponsors
3.5. Pharmaceutical CRO Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.2. PESTEL Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Pharmaceutical CRO Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Pharmaceutical CRO Market Type Movement Analysis
4.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Type, 2024 to 2033 (USD Million)
4.4. Drug Discovery
4.4.1. Drug discovery market estimates and forecasts 2024 to 2033 (USD Million)
4.4.2. Target Validation
4.4.2.1. Target validation market estimates and forecasts 2024 to 2033 (USD Million)
4.4.3. Lead Identification
4.4.3.1. Lead identification market estimates and forecasts 2024 to 2033 (USD Million)
4.4.4. Lead Optimization
4.4.4.1. Lead optimization market estimates and forecasts 2024 to 2033 (USD Million)
4.5. Pre-Clinical
4.5.1. Pre-Clinical market estimates and forecasts 2024 to 2033 (USD Million)
4.6. Clinical
4.6.1. Clinical market estimates and forecasts 2024 to 2033 (USD Million)
4.6.2. Phase I Trial Services
4.6.2.1. Phase I Trial Services market estimates and forecasts 2024 to 2033 (USD Million)
4.6.3. Phase II Trial Services
4.6.3.1. Phase II Trial Services market estimates and forecasts 2024 to 2033 (USD Million)
4.6.4. Phase III Trial Services
4.6.4.1. Phase III Trial Services market estimates and forecasts 2024 to 2033 (USD Million)
4.6.5. Phase IV Trial Services
4.6.5.1. Phase IV Trial Services market estimates and forecasts 2024 to 2033 (USD Million)
Chapter 5. Pharmaceutical CRO Market: Molecule Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Pharmaceutical CRO Market Molecule Type Movement Analysis
5.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Molecule Type, 2024 to 2033 (USD Million)
5.4. Small Molecules
5.4.1. Small Molecules market estimates and forecasts 2024 to 2033 (USD Million)
5.5. Large Molecules
5.5.1. Large Molecules market estimates and forecasts 2024 to 2033 (USD Million)
Chapter 6. Pharmaceutical CRO Market: Service Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Pharmaceutical CRO Market Services Movement Analysis
6.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Service, 2024 to 2033 (USD Million)
6.4. Project Management/Clinical Supply Management
6.4.1. Project Management/Clinical Supply Management market estimates and forecasts 2024 to 2033 (USD Million)
6.5. Data Management
6.5.1. Data Management market estimates and forecasts 2024 to 2033 (USD Million)
6.6. Regulatory/Medical Affairs
6.6.1. Regulatory/Medical Affairs market estimates and forecasts 2024 to 2033 (USD Million)
6.7. Medical Writing
6.7.1. Medical Writing market estimates and forecasts 2024 to 2033 (USD Million)
6.8. Clinical Monitoring
6.8.1. Clinical Monitoring market estimates and forecasts 2024 to 2033 (USD Million)
6.9. Quality Management/ Assurance
6.9.1. Quality Management/ Assurance market estimates and forecasts 2024 to 2033 (USD Million)
6.10. Biostatistics
6.10.1. Bio-statistics market estimates and forecasts 2024 to 2033 (USD Million)
6.11. Investigator Payments
6.11.1. Investigator Payments market estimates and forecasts 2024 to 2033 (USD Million)
6.12. Laboratory
6.12.1. Laboratory market estimates and forecasts 2024 to 2033 (USD Million)
6.13. Patient And Site Recruitment
6.13.1. Patient And Site Recruitment market estimates and forecasts 2024 to 2033 (USD Million)
6.14. Technology
6.14.1. Technology market estimates and forecasts 2024 to 2033 (USD Million)
6.15. Others
6.15.1. Others market estimates and forecasts 2024 to 2033 (USD Million)
Chapter 7. Pharmaceutical CRO Market: Therapeutic Areas Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Pharmaceutical CRO Market Therapeutic Areas Movement Analysis
7.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Therapeutic Areas, 2024 to 2033 (USD Million)
7.4. Oncology
7.4.1. Oncology market estimates and forecasts 2024 to 2033 (USD Million)
7.5. CNS Disorders
7.5.1. CNS Disorders market estimates and forecasts 2024 to 2033 (USD Million)
7.6. Infectious Diseases
7.6.1. Infectious Diseases market estimates and forecasts 2024 to 2033 (USD Million)
7.7. Immunological Disorders
7.7.1. Immunological Disorders market estimates and forecasts 2024 to 2033 (USD Million)
7.8. Cardiovascular Disease
7.8.1. Cardiovascular Disease market estimates and forecasts 2024 to 2033 (USD Million)
7.9. Respiratory Diseases
7.9.1. Respiratory Diseases market estimates and forecasts 2024 to 2033 (USD Million)
7.10. Diabetes
7.10.1. Diabetes market estimates and forecasts 2024 to 2033 (USD Million)
7.11. Ophthalmology
7.11.1. Ophthalmology market estimates and forecasts 2024 to 2033 (USD Million)
7.12. Pain Management
7.12.1. Pain Management market estimates and forecasts 2024 to 2033 (USD Million)
7.13. Other
7.13.1. Other market estimates and forecasts 2024 to 2033 (USD Million)
Chapter 8. Pharmaceutical CRO Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2025 & 2033
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2024 to 2033:
8.4. North America
8.4.1. North America Market Estimates and Forecasts 2024 to 2033 (USD Million)
8.4.2. U.S.
8.4.2.1. Key country dynamics
8.4.2.2. Competitive scenario
8.4.2.3. Regulatory scenario
8.4.2.4. U.S. market estimates and forecasts 2024 to 2033 (USD Million)
8.4.3. Canada
8.4.3.1. Key country dynamics
8.4.3.2. Competitive scenario
8.4.3.3. Regulatory scenario
8.4.3.4. Canada market estimates and forecasts 2024 to 2033 (USD Million)
8.4.4. Mexico
8.4.4.1. Key country dynamics
8.4.4.2. Competitive scenario
8.4.4.3. Regulatory scenario
8.4.4.4. Mexico market estimates and forecasts 2024 to 2033 (USD Million)
8.5. Europe
8.5.1. Europe Market Estimates and Forecasts 2024 to 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key country dynamics
8.5.2.2. Competitive scenario
8.5.2.3. Regulatory scenario
8.5.2.4. UK market estimates and forecasts 2024 to 2033 (USD Million)
8.5.3. Germany
8.5.3.1. Key country dynamics
8.5.3.2. Competitive scenario
8.5.3.3. Regulatory scenario
8.5.3.4. Germany market estimates and forecasts 2024 to 2033 (USD Million)
8.5.4. France
8.5.4.1. Key country dynamics
8.5.4.2. Competitive scenario
8.5.4.3. Regulatory scenario
8.5.4.4. France market estimates and forecasts 2024 to 2033 (USD Million)
8.5.5. Italy
8.5.5.1. Key country dynamics
8.5.5.2. Competitive scenario
8.5.5.3. Regulatory scenario
8.5.5.4. Italy market estimates and forecasts 2024 to 2033 (USD Million)
8.5.6. Spain
8.5.6.1. Key country dynamics
8.5.6.2. Competitive scenario
8.5.6.3. Regulatory scenario
8.5.6.4. Spain market estimates and forecasts 2024 to 2033 (USD Million)
8.5.7. Denmark
8.5.7.1. Key country dynamics
8.5.7.2. Competitive scenario
8.5.7.3. Regulatory scenario
8.5.7.4. Denmark market estimates and forecasts 2024 to 2033 (USD Million)
8.5.8. Sweden
8.5.8.1. Key country dynamics
8.5.8.2. Competitive scenario
8.5.8.3. Regulatory scenario
8.5.8.4. Sweden market estimates and forecasts 2024 to 2033 (USD Million)
8.5.9. Norway
8.5.9.1. Key country dynamics
8.5.9.2. Competitive scenario
8.5.9.3. Regulatory scenario
8.5.9.4. Norway market estimates and forecasts 2024 to 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Market Estimates and Forecasts 2024 to 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key country dynamics
8.6.2.2. Competitive scenario
8.6.2.3. Regulatory scenario
8.6.2.4. Japan market estimates and forecasts 2024 to 2033 (USD Million)
8.6.3. China
8.6.3.1. Key country dynamics
8.6.3.2. Competitive scenario
8.6.3.3. Regulatory scenario
8.6.3.4. China market estimates and forecasts 2024 to 2033 (USD Million)
8.6.4. India
8.6.4.1. Key country dynamics
8.6.4.2. Competitive scenario
8.6.4.3. Regulatory scenario
8.6.4.4. India market estimates and forecasts 2024 to 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key country dynamics
8.6.5.2. Competitive scenario
8.6.5.3. Regulatory scenario
8.6.5.4. Australia market estimates and forecasts 2024 to 2033 (USD Million)
8.6.6. South Korea
8.6.6.1. Key country dynamics
8.6.6.2. Competitive scenario
8.6.6.3. Regulatory scenario
8.6.6.4. South Korea market estimates and forecasts 2024 to 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key country dynamics
8.6.7.2. Competitive scenario
8.6.7.3. Regulatory scenario
8.6.7.4. Thailand market estimates and forecasts 2024 to 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America Market Estimates and Forecasts 2024 to 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key country dynamics
8.7.2.2. Competitive scenario
8.7.2.3. Regulatory scenario
8.7.2.4. Brazil market estimates and forecasts 2024 to 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key country dynamics
8.7.3.2. Competitive scenario
8.7.3.3. Regulatory scenario
8.7.3.4. Argentina market estimates and forecasts 2024 to 2033 (USD Million)
8.8. MEA
8.8.1. MEA Market Estimates and Forecasts 2024 to 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key country dynamics
8.8.2.2. Competitive scenario
8.8.2.3. Regulatory scenario
8.8.2.4. South Africa market estimates and forecasts 2024 to 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key country dynamics
8.8.3.2. Competitive scenario
8.8.3.3. Regulatory scenario
8.8.3.4. Saudi Arabia market estimates and forecasts 2024 to 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key country dynamics
8.8.4.2. Competitive scenario
8.8.4.3. Regulatory scenario
8.8.4.4. UAE market estimates and forecasts 2024 to 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key country dynamics
8.8.5.2. Competitive scenario
8.8.5.3. Regulatory scenario
8.8.5.4. Kuwait market estimates and forecasts 2024 to 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Service Heat Map Analysis
9.3. Pharmaceutical CRO Market Share Analysis,2024
9.4. Company Profiles/Listing
9.4.1. Thermo Fisher Scientific Inc.
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Medpace
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. IQVIA
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. CTI Clinical Trial & Consulting
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Parexel International (MA) Corporation.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. ICON plc
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Laboratory Corporation of America Holdings
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. WuXi AppTec
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Veeda Clinical Research
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
著作権 ©2022 無断複写・転載を禁じます